Finance

Lists
Outlook: 40.0% bullish·0.0% bearish
Go to analysis
VTRS:NASDAQ
Viatris Inc
$17.64
+1.15%
(+0.20) 1D
$17.85
+1.19% (+0.21)
After hours
Closed: Oct 9, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VTRS...
Open
$17.36
High
$17.76
Low
$17.18
Mkt. cap
20.26B
Avg. vol.
8.77M
Volume
8.83M
Dividend
2.72%
Quarterly dividend
$0.12
Ex-dividend date
Aug 21, 2026
52-wk high
$18.43
52-wk low
$9.69
EPS
-$0.36
Beta
0.86
Shares outstanding
1.15B
No. of employees
30K
Open
$17.36
High
$17.76
Low
$17.18
Mkt. cap
20.26B
Avg. vol.
8.77M
Volume
8.83M
Dividend
2.72%
Quarterly dividend
$0.12
Ex-dividend date
Aug 21, 2026
52-wk high
$18.43
52-wk low
$9.69
EPS
-$0.36
Beta
0.86
Shares outstanding
1.15B
No. of employees
30K
News stories
From web sources and news partners
Profile
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020. The name of the corporation comes from the Latin words via, meaning path, and tris, which means three, referring to the path to three main objectives the corporation set: expanding access to medicines, meeting patient needs through innovation, and earning the trust of the healthcare community. Viatris ranked 254th on the 2021 Fortune 500 rankings of the largest United States corporations based on its 2020 total revenue. In 2026, Viatris ranked 100 on Time Magazine's World's Most Impactful Companies. Wikipedia
About Viatris Inc
CEOScott A. Smith
Employees30K
FoundedNov 16, 2020
HeadquartersCanonsburg, Pennsylvania, United States
SectorPharmaceutical industry
Websiteviatris.com
Analyst ratings
Based on 9 analysts giving stock ratings to VTRS in the past 3 months
Buy
Buy
5
Hold
3
Sell
1
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for VTRS in the last 3 months.
Highest
Current $17.64
$26.00 (+47.39%)
Average
$20.00 (+13.38%)
Lowest
$13.00 (-26.30%)
Analyst
Recommendation
Action
Price target
Projected
Date
Salveen Richter
Goldman Sachs
Hold
Maintained
$20.00
+13.4%
10/08/2026
Jason Gerberry
Bank of America Securities
Sell
Maintained
$16.00
-9.3%
10/08/2026
Ashwani Verma
UBS
Buy
Maintained
$26.00
+47.4%
10/05/2026
Les Sulewski
Oppenheimer
Buy
Initiated
$25.00
+41.7%
09/23/2026
Unknown Analyst
Oppenheimer
Buy
Initiated
$25.00
+41.7%
09/23/2026
David Amsellem
Piper Sandler
Hold
Reiterated
$13.00
-26.3%
09/16/2026
Daniel Clark
Leerink Partners
Buy
Initiated
$20.00
+13.4%
09/09/2026
Jasper Hellweg
Argus Research
Buy
Maintained
$20.00
+13.4%
09/08/2026
Glen Santangelo
Barclays
Buy
Reiterated
$22.00
+24.7%
08/17/2026
Chris Schott
J.P. Morgan
Hold
Maintained
$18.00
+2%
08/10/2026
Unknown Analyst
Jefferies
Buy
Maintained
$17.00
-3.6%
03/20/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
$0.69 / $0.60
+15.04%beat
Revenue / Est. (USD)
3.76B / 3.67B
+2.36%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
3.76B
3.70B
3.52B
3.76B
Cost of goods sold
2.26B
2.21B
2.14B
2.19B
Cost of revenue
2.26B
2.21B
2.14B
2.19B
Research and development expenses
244.80M
271.20M
245.80M
245.20M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
848.50M
933.40M
893.40M
855.00M
Operating expense
1.09B
1.20B
1.14B
1.10B
Total operating expenses
3.36B
3.42B
3.28B
3.29B
Operating income
404.60M
288.20M
238.60M
471.50M
Other non operating income
-135.90M
44.90M
-1.80M
14.40M
EBT including unusual items
-7.90M
-343.00M
-247.30M
-64.00M
EBT excluding unusual items
318.70M
188.00M
146.20M
365.40M
Income tax expense
120.30M
-2.90M
-423.70M
54.80M
Effective tax rate
-1,522.78%
0.85%
171.33%
-85.62%
Other operating expenses
-
-
-
-
Net income
-128.20M
-340.10M
176.40M
-118.80M
Net profit margin
-3.41%
-9.18%
5.02%
-3.16%
Earnings per share
0.67
0.57
0.59
0.69
Interest and investment income
-
-
-
-
Interest expense
-119.60M
-119.60M
-120.10M
-120.70M
Net interest expenses
-119.60M
-119.60M
-120.10M
-120.70M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.09B
981.10M
914.70M
1.14B
Gain or loss from assets sale
-1.60M
21.90M
13.90M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps